Alkermes plc.

ALKS

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001520262

A

strongest fifth of 367 graded peers in healthcare

rank 31 of 367; percentile 8.2; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard

Profitability	B percentile 31.7
Solvency	B percentile 33.3
Growth and financing	B percentile 33.7
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $2.5B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Feb 25, 2026 263 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026
Last close	$47.01 2026-11-13; market equity $7.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

" in this Annual Report. If we are unable to compete successfully in the highly competitive biopharmaceutical industry, our business, financial condition, cash flows and results of operations could be materially adversely affected. Our revenues from sales of our products may decrease or grow at a slower than expected rate due to many factors. We cannot be assured that our products will be, or will continue to be, accepted in the U.S. or markets outside the U.S. or that we will be able to maintain or increase sales of our products.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 31.7						
Gross profitability	51.4%	32.3%		22.5	365	2025-12-31
Return on invested capital	not computable	9.3%				

latest aligned inputs end 2016-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(12.3%)	(6.6%)	35.6	799	2025-12-31
Gross margin stability, five years	2.1 pts	2.8 pts	36.9	242	2025-12-31
Solvency, sleeve percentile 33.3					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	6.24	(0.31)	15.5	743	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	3.55x	2.96x	51.1	825	2025-12-31
Growth and financing, sleeve percentile 33.7					
Revenue growth, three-year compound	9.9%	10.1%	51.2	411	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	213.1%	37.1%	14.6	104	2025-12-31
Asset growth, three years	8.2%	2.3%	34.4	693	2025-12-31
Net share issuance, one year	2.5%	2.4%	34.5	627	2026-02-20

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
26	Ideaya Biosciences, Inc. (IDYA)	6.8	A	
27	Gyre Therapeutics, Inc. (GYRE)	7.1	A	fortress balance sheet
28	Hims & Hers Health, Inc. (HIMS)	7.4	A	
29	iRhythm Holdings, Inc. (IRTC)	7.7	A	fortress balance sheet
30	Veracyte, Inc. (VCYT)	7.9	A	
31	Alkermes plc. (ALKS)	8.2	A	
32	Viridian Therapeutics, Inc.\DE (VRDN)	8.5	A	dilution, fortress balance sheet
33	Si-Bone, Inc. (SIBN)	8.7	A	fortress balance sheet
34	Xtant Medical Holdings, Inc. (XTNT)	9.0	A	fortress balance sheet
35	Viemed Healthcare, Inc. (VMD)	9.3	A	
36	TG Therapeutics, Inc. (TGTX)	9.6	A	

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	32.0%	(1.5%)	70
Distance from 52-week high	(14.8%)	(32.0%)	66
EBIT to enterprise value	2.9%	(1.8%)	67
Free cash flow yield	6.1%	(1.0%)	86
Book value to price	0.24	0.29	44

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.19	0.29	39
Composite equity issuance, five years	5.4%	19.1%	34
Relative strength against the sector, log excess return	0.11	(0.18)	70

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$631.3M
Operating cash flow, four quarters	$243.0M
Months of runway	not finite
Days since last periodic filing	12 (10-Q received Nov 3, 2026)
Median daily dollar volume, 63 sessions	$77.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.5B	2025-12-31	2026-02-25	10-K	26-068925
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$196.5M	2025-12-31	2026-02-25	10-K	26-068925
3	assets	us-gaap:Assets	$2.5B	2025-12-31	2026-02-25	10-K	26-068925
4	operating income	us-gaap:OperatingIncomeLoss	-$208.7M	2016-12-31	2019-02-15	10-K	19-003060
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$214.4M	2016-12-31	2019-02-15	10-K	19-003060
6	income tax	us-gaap:IncomeTaxExpenseBenefit	-$5.9M	2016-12-31	2019-02-15	10-K	19-003060
7	total debt	us-gaap:LongTermDebt	$283.7M	2016-12-31	2017-02-17	10-K	17-000007
8	book equity	us-gaap:StockholdersEquity	$1.2B	2016-12-31	2020-02-13	10-K	20-004489
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$186.4M	2016-12-31	2018-02-16	10-K	18-000016
10	total debt	us-gaap:LongTermDebt	$349.9M	2015-12-31	2017-02-17	10-K	17-000007
11	book equity	us-gaap:StockholdersEquity	$1.3B	2015-12-31	2019-02-15	10-K	19-003060
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$181.1M	2015-12-31	2018-02-16	10-K	18-000016
13	net income	us-gaap:NetIncomeLoss	$241.7M	2025-12-31	2026-02-25	10-K	26-068925
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$520.8M	2025-12-31	2026-02-25	10-K	26-068925
15	assets	us-gaap:Assets	$2.1B	2024-12-31	2026-02-25	10-K	26-068925
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.6B	2024-12-31	2026-02-25	10-K	26-068925
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$245.3M	2024-12-31	2026-02-25	10-K	26-068925
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.7B	2023-12-31	2026-02-25	10-K	26-068925
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$253.0M	2023-12-31	2026-02-25	10-K	26-068925
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2022-12-31	2025-02-12	10-K	25-019011
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$218.1M	2022-12-31	2025-02-12	10-K	25-019011
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.2B	2021-12-31	2024-02-21	10-K	24-017883
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$197.3M	2021-12-31	2024-02-21	10-K	24-017883
24	current assets	us-gaap:AssetsCurrent	$1.9B	2025-12-31	2026-02-25	10-K	26-068925
25	current liabilities	us-gaap:LiabilitiesCurrent	$543.4M	2025-12-31	2026-02-25	10-K	26-068925
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$734.8M	2025-12-31	2026-02-25	10-K	26-068925
27	operating income	us-gaap:OperatingIncomeLoss	$254.0M	2025-12-31	2026-02-25	10-K	26-068925

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	book equity	us-gaap:StockholdersEquity	$1.8B	2025-12-31	2026-02-25	10-K	26-068925
29	liabilities	us-gaap:Liabilities	$667.7M	2025-12-31	2026-02-25	10-K	26-068925
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$94.3M	2016-12-31	2019-02-15	10-K	19-003060
31	operating income	us-gaap:OperatingIncomeLoss	$414.1M	2023-12-31	2026-02-25	10-K	26-068925
32	interest expense	us-gaap:InterestExpense	$23.0M	2023-12-31	2024-02-21	10-K	24-017883
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$40.4M	2025-12-31	2026-02-25	10-K	26-068925
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$439.1M	2024-12-31	2026-02-25	10-K	26-068925
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$33.5M	2024-12-31	2026-02-25	10-K	26-068925
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$401.4M	2023-12-31	2026-02-25	10-K	26-068925
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$48.0M	2023-12-31	2026-02-25	10-K	26-068925
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$21.0M	2022-12-31	2025-02-12	10-K	25-019011
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$38.3M	2022-12-31	2025-02-12	10-K	25-019011
40	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$27.2M	2025-12-31	2026-02-25	10-K	26-068925
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$291.4M	2025-12-31	2026-02-25	10-K	26-068925
42	income tax	us-gaap:IncomeTaxExpenseBenefit	$49.8M	2025-12-31	2026-02-25	10-K	26-068925
43	current assets	us-gaap:AssetsCurrent	$1.4B	2024-12-31	2026-02-25	10-K	26-068925
44	current liabilities	us-gaap:LiabilitiesCurrent	$465.2M	2024-12-31	2026-02-25	10-K	26-068925
45	assets	us-gaap:Assets	$2.1B	2023-12-31	2025-02-12	10-K	25-019011
46	assets	us-gaap:Assets	$2.0B	2022-12-31	2024-02-21	10-K	24-017883
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	166,649,934	2026-02-20	2026-02-25	10-K	26-068925
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	162,614,067	2025-02-07	2025-02-12	10-K	25-019011

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.